950769-51-4

Basic information

• Product Name: N-[5-(1,1-Dimethylethyl)-3-isoxazolyl]-N'-[4-(7-hydroxyimidazo[2,1-b]benzothiazol-2-yl)phenyl]urea
• Synonyms: N-[5-(1,1-Dimethylethyl)-3-isoxazolyl]-N'-[4-(7-hydroxyimidazo[2,1-b]benzothiazol-2-yl)phenyl]urea
• CAS NO: 950769-51-4
• Molecular Formula: C23H21N5O3S
• Molecular Weight: 447.50954
• Mol File: 950769-51-4.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-[5-(1,1-Dimethylethyl)-3-isoxazolyl]-N'-[4-(7-hydroxyimidazo[2,1-b]benzothiazol-2-yl)phenyl]urea(CAS DataBase Reference)
• NIST Chemistry Reference: N-[5-(1,1-Dimethylethyl)-3-isoxazolyl]-N'-[4-(7-hydroxyimidazo[2,1-b]benzothiazol-2-yl)phenyl]urea(950769-51-4)
• EPA Substance Registry System: N-[5-(1,1-Dimethylethyl)-3-isoxazolyl]-N'-[4-(7-hydroxyimidazo[2,1-b]benzothiazol-2-yl)phenyl]urea(950769-51-4)

Safety Data

• Hazardous Substances Data: 950769-51-4(Hazardous Substances Data)

Usage

General Description

N-[5-(1,1-Dimethylethyl)-3-isoxazolyl]-N'-[4-(7-hydroxyimidazo[2,1-b]benzothiazol-2-yl)phenyl]urea is a complex chemical compound with a long name. It is a urea derivative that consists of isoxazole, imidazo[2,1-b]benzothiazole, and phenyl groups. The compound has potential applications in pharmaceutical research and drug development due to its unique molecular structure and potential biological activity. It may have properties that make it useful for treating certain medical conditions or as a research tool in the study of biological processes. However, further research is necessary to fully understand the properties and potential uses of this chemical.

Upstream product

• 1132827-30-5 4-(7-hydroxyimidazo[2,1-b]benzothiazol-2-yl)benzenamine 
• 55809-53-5 5-tert-butyl-3-isoxazolyl isocyanate 

Relevant articles and documents

Identification of N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2- morpholin-4-yl-ethoxy)imidazo-[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor

Treatment of AML patients with small molecule inhibitors of FLT3 kinase has been explored as a viable therapy. However, these agents are found to be less than optimal for the treatment of AML because of lack of sufficient potency or suboptimal oral pharma

Imidazolothiazole compounds for the treatment of disease

Compounds, compositions and methods are provided for modulating the activity of receptor kinases and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by receptor kinases.